Logo

American Heart Association

  108
  0


Final ID: WMP5

Comparative analysis of methods to derive number needed to treat over the entire range of global disability on the modified Rankin Scale

Abstract Body: Background: Number needed to treat (NNT) is an intuitive measure of treatment benefit/harm to both clinicians and patients. For ordinal endpoints, NNTs derived by dichotomously collapsing scales are easily calculated but almost always underestimate the amount of benefit a treatment confers. Several methods have been described to derive NNT for ordinal outcomes. We aimed to directly compare the performance of each of the most widely described methods of ordinal NNT derivation.

Methods: NNT was calculated for eight stroke clinical rials/meta-analyses purposively selected to include small, moderate and large treatment effects and diverse treatment types, including thrombolysis (NINDS tPA, IST3), thrombectomy (HERMES, AURORA, Large Core EVT), surgery for AIS (Hemicraniectomy), surgery for ICH (ENRICH), and blood pressure control (OPTIMAL BP). We derived benefit per hundred treated (BPH, same as absolute risk reduction) and NNT using four Permutation Methods (CMH test with tied pairs ignored, divided in half, assigned by NIHSS outcome, and by better than model expectations) and three Joint Outcome Table Methods (Multi-sampling, Min-Max, and Expert Panel).

Results: The net BPH and NNT values derived for each trial using each method are shown in the Table. Overall, the magnitude of treatment effect estimates rendered by Permutation methods were substantially lower than by Joint Outcome methods Table methods. In 4 of 8 trials, Permutation method estimates were lower than dichotomous estimates – a biologic impossibility. Among the automatic Joint Outcome Table Methods, the repetitive Multi-sampling technique yielded mildly lower estimates than the algorithmic Min-Max technique.

Conclusions: Permutation (Cochran–Mantel–Haenszel) ordinal NNT derivation methods systematically underestimate treatment benefit magnitude due to bias towards the null from calculation-related nondifferential misclassification. Joint Outcomes Table methods may be preferred for future clinical trials that report net NNT for ordinal outcomes.
  • Mistry, Eva  ( University of Cincinnati , Cincinnati , Ohio , United States )
  • Gornbein, Jeffrey  ( UCLA school of Medicine , Los Angeles , United States Minor Outlying Islands )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Author Disclosures:
    Eva Mistry: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Translational Sciences:Active (exists now) ; Research Funding (PI or named investigator):Patient Centered Outcomes Research Institute:Active (exists now) ; Research Funding (PI or named investigator):National Institutes of Health:Active (exists now) ; Consultant:SilverCreek Pharmaceuticals:Active (exists now) ; Consultant:RAPID AI:Past (completed) ; Consultant:AbbVie:Active (exists now) | Jeffrey Gornbein: DO NOT have relevant financial relationships | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now)
Meeting Info:
Session Info:

Acute Treatment: Systemic Thrombolysis and Cerebroprotection Moderated Poster Tour

Wednesday, 02/05/2025 , 06:00PM - 07:00PM

Moderated Poster Abstract Session

More abstracts on this topic:
A randomized controlled trial of antithrombotic therapy in ischemic stroke patients with non-valvular atrial fibrillation and atherosclerosis: The ATIS-NVAF trial

Okazaki Shuhei, Uchida Kazutaka, Asakura Koko, Omae Katsuhiro, Yamamoto Haruko, Hirano Teruyuki, Toyoda Kazunori, Iguchi Yasuyuki, Noguchi Teruo, Okada Yasushi, Kitagawa Kazuo, Tanaka Kanta, Sakai Nobuyuki, Yamagami Hiroshi, Yazawa Yukako, Doijiri Ryosuke, Koga Masatoshi, Ihara Masafumi, Yamamoto Shiro, Kamiyama Kenji, Honda Yuko

A First-In-Human Phase 1 Study of the Safety, Tolerability, and Pharmacodynamics of REGN7544, a Novel Natriuretic Peptide Receptor 1–Blocking Monoclonal Antibody

Ahmed Mohsin, Morton Lori, Olenchock Benjamin, Herman Gary, Wynne Chris, Marin Ethan, Tuckwell Katie, Xu Meng, Cheng Xiping, Redington Emily, Koyani Bharatkumar, Mateo Katrina, Thakur Mazhar, Devalaraja-narashimha Kishor

More abstracts from these authors:
Increase in Acute Ambient Particulate Matter Before Stroke is Associated with Deterioration in Early Stroke Outcomes

Shkirkova Kristina, Mack William, Saver Jeffrey, Mcconnell Rob, Farzan Shohreh, Tang-tan Angela, Qiu Chenyu, Pavlovic Nathan R, Vassar Stefanie, Lurmann Frederick, Sanossian Nerses, Gornbein Jeffrey, Chen Zhanghua

Treatment with Endovascular Intervention for Stroke Patients with Existing Disability (TESTED): A Comparative Effectiveness Study

Mistry Eva, Sucharew Heidi, Griffin Naima, Syori Laura, Khandwala Vivek, Wechsler Paul, Saver Jeffrey, Mocco J

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)